

Emcure Pharmaceuticals strengthens its commitment to energy conservation, signs PPA with Sunsire Energy for solar power

Pune, July 26, 2024 – Emcure Pharmaceuticals Ltd., one of the leading Indian pharmaceutical company with a differentiated product portfolio, together with its subsidiary Gennova Biopharmaceuticals Limited announces the signing of a 22.78 MWp DC Solar Power Purchase Agreement (PPA) with Sunsire Energy, one of India's leading renewable power producers. Through this partnership, Emcure and Gennova will receive approximately 36 million units of clean, renewable energy annually for their Pune plants. The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants with green power and offsetting 29,765.71 metric tons of CO₂e annually. This agreement represents a substantial step forward in Emcure's commitment to sustainability. Pursuant to the PPA, Emcure and Gennova have signed a Shareholders Agreement to acquire stake in Sunsire Solarpark Twelve Private Limited, for the purchase of solar power under a group captive scheme as per the Electricity Act, 2023 and applicable rules thereunder.

With a strong presence in over 70 countries, Emcure Pharmaceuticals has been a trusted name in the pharmaceutical industry, consistently focusing on improving lives through innovative and quality pharmaceutical solutions. Sunsire will be supplying this power from its 150 MWp DC solar plant in Solapur, Maharashtra. This new agreement will further strengthen Emcure's commitment to integrating sustainability across operations in its plants to minimize environmental impact.

Commenting on the PPA agreement, **Mr. Sunil Mehta, Whole-time Director of Emcure Pharmaceuticals Ltd.**, said: "At Emcure, we are dedicated not only to improving lives through innovation and research for our differentiated portfolio but also through efficient and environment-friendly manufacturing processes. Our partnership with Sunsire Energy is a testament to promoting innovative solutions in the pharmaceutical industry to reduce the industry's carbon footprint by embracing the power of renewable energy. Emcure is proud to be leading the adoption of solar power in the pharmaceutical industry in India. We look forward to continuing our collaboration with Sunsire Energy to achieve new milestones in our green energy journey."

Mr. Shashank Sharma, Founder and CEO of Sunsire Energy, commented: "We are thrilled to onboard Emcure Pharmaceuticals, a global leader in the pharmaceutical industry, to our esteemed family of customers. This PPA demonstrates Sunsire's dedication to facilitating the renewable energy transition for leading corporations in the pharmaceutical sector. By working together, we are not only powering Emcure's facilities with clean energy but also driving broader environmental stewardship within the industry."

Emcure Pharmaceuticals has always been deeply committed to environmental sustainability, integrating green initiatives and eco-friendly practices across all operations. Besides adhering to current good manufacturing practices (cGMP) and international regulatory standards, Emcure's facilities have energy-efficient equipment, follow advanced waste management and pollution control systems, and undertake rainwater harvesting. True to its philosophy of Reduce, Reuse and

Recycle, Emcure's R&D team has been exploring measures for solvent recycling and recovery for reuse. In addition, Emcure's 13 manufacturing plants are equipped to ensure Zero Liquid Discharge systems and Effluent Treatment Plants along with ensuring treatment of 100% of waste generated. These measures reflect Emcure Pharmaceutical's dedication to protecting the environment and promoting sustainable development.

About Emcure Pharmaceuticals Limited.

Emcure Pharmaceuticals Ltd. (EPL) [BSE: 544210] is a leading Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products. Known for its commitment to innovation, quality, and patient-centricity, Emcure is an R&D driven company that develops and manufactures a wide range of differentiated pharmaceutical products designed to improve patient health and well-being across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of Domestic Sales for MAT March 2024. Emcure is present in 70+ countries globally including Europe and Canada.

To know more about Emcure, please visit: <https://www.emcure.com/>

About Sunsure Energy:

Founded in 2014, Sunsure Energy is the preferred renewable energy solutions provider for India's leading businesses transitioning to green power. As a leading Independent Power Producer (IPP), Sunsure enables businesses across India to embrace clean energy with ease and confidence through long-term Power Purchase Agreements (PPAs) that offset up to 70% of power use to renewable energy through a mix of solar, wind, and battery storage technologies. Sunsure is backed by Partners Group AG with an equity commitment of \$400 million towards its vision of building the largest industrial decarbonization company in India and SE Asia. With 500 MW of assets under operation, 2.5 GW of renewable energy capacity under construction, and a target of 5 GW by the end of 2028, Sunsure Energy is committed to powering India's energy independence and transforming every Indian business with green energy.